Hays Advisory’s Enanta Pharmaceuticals ENTA Stock Holding History

Hays Advisory’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-116,939	Closed	-$3.92M	–	80
2016 Q4	$3.92M	Sell	116,939 -39,608	-25%	-$1.14M	0.87%	31
2016 Q3	$4.17M	Sell	156,547 -16,010	-9%	-$372K	0.69%	35
2016 Q2	$3.81M	Sell	172,557 -28,369	-14%	-$743K	0.59%	37
2016 Q1	$5.9M	Sell	200,926 -18,172	-8%	-$506K	0.83%	34
2015 Q4	$7.24M	Sell	219,098 -28,758	-12%	-$937K	1.23%	32
2015 Q3	$8.96M	Buy	+247,856	New	+$10.6M	1.35%	34

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

MCM

Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Hays Advisory's ENTA Position: Q1 2017 in Review

Hays Advisory sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 116,939 shares — an estimated $3.92M sold.

Hays Advisory first reported a position in ENTA in Q3 2015 and held it in 6 quarters. The position peaked at $8.96M in Q3 2015. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

Hays Advisory reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Hays Advisory sold 116,939 Enanta Pharmaceuticals shares in Q1 2017, an estimated $3.92M.
Hays Advisory first reported a position in Enanta Pharmaceuticals in Q3 2015 and held it in 6 quarters.
Hays Advisory's Enanta Pharmaceuticals position peaked at $8.96M in Q3 2015.
126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Hays Advisory's 13F filing for Q1 2017, filed 13 Apr 2017.